Annual Henry Ford Cancer Thoracic Multidisciplinary Symposium (2025)

Saturday, November 15, 2025, 7:00 AM - 2:45 PM, The Henry Hotel, Dearborn, MI


AMA PRA Category 1 Credits™ (6.00 hours), ABIM MOC Part 2 (6.00 hours), Non-Physician Attendance (6.00 hours)

The 3rd Annual Henry Ford Cancer Thoracic Multidisciplinary Symposium is an educational program offering the latest updates in the diagnosis and multidisciplinary management of lung cancer. Through expert lectures, panel discussions, and interactive case sessions, participants will: • Review advances in perioperative immunotherapy, targeted therapy, and surgical approaches for early stage NSCLC • Explore updates in systemic therapy for metastatic NSCLC, including antibody drug conjugates, bispecifics, and novel biomarkers (HER2, MET, ROS1, NRG) • Examine the evolving treatment landscape of small cell lung cancer • Gain insight from a patient advocate on the patient experience in lung cancer care and research. This symposium is designed for oncologists, surgeons, radiation oncologists, pulmonologists, and other members of the thoracic cancer care team seeking practical, evidence based updates to improve patient outcomes.

1. Stay up to date with the latest data and clinical practices in the perioperative and metastatic management of NSCLC.
2. Integrate emerging treatments such as bispecific antibodies, antibody-drug conjugates (ADCs), and novel targeted therapies (e.g., HER2, MET, ROS1, NRG) into clinical decision-making.
3. Understand the evolving role of surgery in advanced-stage NSCLC.
4. Recognize the importance of biomarker testing and targeted therapy in early-stage and metastatic NSCLC.
5. Gain insights into current approaches to small cell lung cancer (SCLC), including new standards and evolving paradigms.
6. Appreciate the patient's voice in treatment planning and research, through dedicated advocacy discussions.
7. Enhance their multidisciplinary collaboration by discussing real-world, case-based scenarios with peers across specialties.

Henry Ford Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

 

DESIGNATION STATEMENT:

Henry Ford Health designates this live course for a maximum of 6.00 AMA PRA Category 1 Credit(s) TM. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

 

FACULTY/PLANNING COMMITTEE DISCLOSURE STATEMENT: 

 In compliance with the ACCME standards for Commercial Support, all individuals in a position to control/influence the content of this activity are required to disclose all financial interests of their own with any ACCME defined commercial interests for the past 24 months and/or non-FDA approved use of a drug or a device that is included in the presentation. All financial relationships have been mitigated prior to the commencement of the activity.

 

ACCESSIBILITY STATEMENT: 

Henry Ford Health provides qualified interpreters and other aids for Deaf, DeafBlind, and Hard-of-Hearing persons at no cost. To request assistance, contact the event coordinator: [email protected]. Please allow a minimum of 3 days to process this request.

Cancellation Policy

Please send cancellation requests to [email protected].

Henry Ford Health Office of Continuing Medical Education reserves the right to cancel or postpone this program if necessary; in the event of cancellation, course fees will be fully refunded. We are not responsible for other costs incurred such as non-refundable airline tickets or hotel penalties.

The Henry Ford Health Office of Continuing Medical Education adheres to ACCME Criteria, Standards and Policies regarding industry support of continuing medical education. Disclosure of faculty and their commercial relationships will be made prior to the activity.

Mitigation of Relevant Financial Relationships

Henry Ford Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.